NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Idelalisib for treating chronic lymphocytic leukaemia - NICE TAG TA359

Idelalisib for treating chronic lymphocytic leukaemia - NICE TAG TA359

1.1 Idelalisib, in combination with rituximab, is recommended:

  • for untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation or

  • for chronic lymphocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months.

    Idelalisib is recommended only if the company provides the drug with the discount agreed in the simple discount agreement.

1.2 People whose treatment with idelalisib is not recommended in this NICE guidance but was started within the NHS before this guidance was published should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta359

 

Site by Devopa
© Copyright 2019 NHS. All rights reserved.